For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
BUSINESS
Boehringer Ingelheim Reports 14.1% Increase in Operating Profit to 2,114 Million Euro in 2013
Andreas Barner, chairman of the board of Boehringer Ingelheim (BI) of Germany, reported at a business briefing held at its head office in Germany on April l5 that the company’s sales in 2013 fell 4.3% (+1.4%, currency-adjusted) compared to the…
To read the full story
BUSINESS
- Lilly’s Pediatric Development Efforts Bore Fruit This Year: Japan CMO
November 8, 2024
- Santen Bags Commercial Rights to Uveitic Macular Edema Drug in China
November 8, 2024
- Keytruda Grabs Top-Selling Crown for 13th Month in October: Encise
November 8, 2024
- UCB to End Cimzia Partnership with Astellas in Japan
November 7, 2024
- Chugai to Discontinue Sale of Rocaltrol in Japan
November 7, 2024
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…